This clinical trial is focused on studying a type of uterine cancer known as mismatch repair deficient endometrial cancer. The treatment being tested is a medication called pembrolizumab, which is also known by its brand name, KEYTRUDA. Pembrolizumab is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream through a vein. The purpose of this study is to evaluate how effective pembrolizumab is in treating this specific type of uterine cancer before surgery.
Participants in the study will receive pembrolizumab over a series of 9 treatment cycles. The main goal is to see how many patients experience a significant reduction in their cancer after these cycles. This reduction is referred to as a major pathologic response, which means the cancer has shrunk significantly when examined under a microscope. The study will also look at other factors, such as how long patients remain free from cancer recurrence after treatment and the safety of using pembrolizumab in this way.
The trial aims to gather information that could lead to further research comparing this treatment approach to other standard treatments. By understanding how pembrolizumab works in this setting, researchers hope to improve treatment options for patients with mismatch repair deficient uterine cancer in the future.
The Netherlands 
